- Molecular NameDidanosine
- SynonymDDI; Dideoxyinosine
- Weight236.231
- Drugbank_IDDB00900
- ACS_NO69655-05-6
- Show 3D model
- LogP (experiment)-1.26
- LogP (predicted, AB/LogP v2.0)-1.09
- pka9.12
- LogD (pH=7, predicted)-1.09
- Solubility (experiment)24.7 mg/mL
- LogS (predicted, ACD/Labs)(ph=7)-1.51
- LogSw (predicted, AB/LogsW2.0)37.54
- Sw (mg/ml) (predicted, ACD/Labs)7.25
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds2
- TPSA88.74
- StatusFDA approved
- AdministrationN/A
- PharmacologyA reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART).
- Absorption_valueN/A
- Absorption (description)Didanosine is rapidly absorbed and reduced by 50% in the presence of food.
- Caco_2N/A
- Bioavailability38.0
- Protein binding5.0
- Volume of distribution (VD)1.00 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is hydrolysed in the acid medium of the stomach and is therefore given by mouth with pH buffers or antacids. Concentrations in CSF are about 20% of those in plasma 1 h after intravenous infusion.
- Half life1.4 h
- ExcretionThe drug is extensively metabolised to the active antiviral metabolite dideoxyadenosine triphosphate, as well as uric acid. Acid hydrolysis may also occur to produce hypoxanthine. About 35 to 60% of a dose is excreted unchanged in urine by glomerular filtration and active tubular secretion. It is partially cleared by haemodialysis but not by peritoneal dialysis.
- Urinary Excretion36
- Clerance16 ml/min/kg
- ToxicitySide effects include pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia and hepatic dysfunction
- LD50 (rat)N/A
- LD50 (mouse)N/A